Weekly recap: VMC, WST, PNFP, MTB, EXEL
Good evening. Here are the US stocks the public conversation moved on most this past week, September 7 to September 13, 2026, and what news, retail investors and analysts said about them.
How to read each name below: first line = how morningowl sentiment moved on its biggest day of the week (the weekday shown), second = where it stood that day (-100 to +100).
Analyst commentary centered on Wells Fargo's shift to Underweight from Equal-Weight, alongside a price target cut to $254 from $305. Retail chatter echoed that same downgrade while flagging a fresh 52-week low and debating whether to average down near the $230 level. News coverage placed the move in a broader context, noting Vulcan Materials among four downgrades tied to weaker outlooks.
All three groups aligned on a cautious read, differing mainly in emphasis: analysts on the rating change, retail on price levels, and news on the sector-wide sweep.
Both groups are centered on the same development: UBS reiterating its favorable rating on WST and lifting its price target to $415 from $340.
Analyst commentary frames it plainly as the reaffirmed favorable stance paired with the higher price target.
News commentary adds the specific attribution, naming UBS analyst Doug Schenkel behind the move. The two groups align fully in direction and substance, differing only in that the news side supplies the analyst's name.
Both groups center on Morgan Stanley's favorable initiation of coverage at a $137 price target.
Analyst commentary frames it simply as a new favorable rating with that figure attached.
News commentary adds the rationale from analyst Ryan Kenny, tying the favorable stance to Pinnacle's positioning to grow faster than peers following its Synovus merger. The two groups align closely, differing mainly in that the news side supplies the merger catalyst behind the same bullish view.
Both groups center on the same Morgan Stanley action: analyst Manan Gosalia's rating change on M&T Bank from Equal-Weight to Overweight, with the price target lifted to $304 from $253.
Analyst commentary focused squarely on that favorable revision.
News commentary echoed it, attaching the analyst's name to the upgrade. The two groups align in direction, with no meaningful divergence between them.
Retail commentary was fixated on a bearish thesis built around cabozantinib (CABOMETYX), arguing that FDA full approval of Handa's Taiwanese generic on September 3, 2026, paired with Exelixis quietly dismissing its patent suit and a failed citizen petition, threatens the drug's roughly $2B in annual revenue, a case made explicitly through put positions. Both the news and analyst groups, by contrast, centered on the same item: Exelixis's presentation at the Wells Fargo Healthcare Conference, offering no directional read on the generic question. The groups thus diverge sharply in focus, with retail pressing a cautious, generic-driven concern that the conference-focused coverage did not address.
🦉 a busier week than most, leaning more positive than negative.
Subscribers get the same read every market morning. https://www.morningowl.io/pricing/
This is not investment advice. morningowl is a publisher, not a registered investment adviser. We may hold positions in any security mentioned. Past performance and historical commentary patterns do not predict future results. Our data and analysis are provided "as is" and may contain inaccuracies; we accept no liability for errors or for any decisions made in reliance on them.
Important: please read
morningowl publishes information, not financial advice. Nothing we publish is a recommendation, solicitation, or offer to buy or sell any security, and nothing here should be taken as investment, legal, tax, or accounting advice. We are not a registered investment adviser, broker-dealer, or financial planner, and no content constitutes a fiduciary relationship of any kind. Our notes describe aggregated public commentary and may be incomplete, delayed, or wrong. Markets carry risk, including loss of principal. Always do your own research and consult a licensed professional before making any financial decision. You are solely responsible for your own decisions.